These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23082962)

  • 1. Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.
    Cheng X
    Cardiovasc Ther; 2013 Aug; 31(4):e19-26. PubMed ID: 23082962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The controversial role of B-vitamins in cardiovascular risk: An update.
    Ntaios G; Savopoulos C; Grekas D; Hatzitolios A
    Arch Cardiovasc Dis; 2009 Dec; 102(12):847-54. PubMed ID: 19963194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease.
    Debreceni B; Debreceni L
    Cardiovasc Ther; 2014 Jun; 32(3):130-8. PubMed ID: 24571382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine and cardiovascular disease: a review of the evidence.
    Wierzbicki AS
    Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
    Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
    G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine in lipoprotein apheresis patients--retrospective data analysis in apheresis center of a university hospital.
    Tselmin S; Rodionov RN; Müller G; Bornstein S; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):123-8. PubMed ID: 23357153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine is not so paradoxical.
    Klevay LM
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):e160; author reply e161. PubMed ID: 18799792
    [No Abstract]   [Full Text] [Related]  

  • 10. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?
    Abraham JM; Cho L
    Cleve Clin J Med; 2010 Dec; 77(12):911-8. PubMed ID: 21147945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of hyperhomocysteinemia.
    Herrmann W
    Clin Lab; 2006; 52(7-8):367-74. PubMed ID: 16955635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases?
    Debreceni B; Debreceni L
    Cardiovasc Ther; 2012 Aug; 30(4):227-33. PubMed ID: 21884001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disturbances of homocysteine metabolism as a risk factor of cardiovascular diseases development: effect on prognosis and possibilities of correction with drugs].
    Shakhmatova OO; Komarov AL; Panchenko EP
    Kardiologiia; 2010; 50(1):42-50. PubMed ID: 20144157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine-lowering trials for prevention of heart disease and stroke.
    Clarke R
    Semin Vasc Med; 2005 May; 5(2):215-22. PubMed ID: 16047274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Homocysteine, folic acid, group B vitamins and cardiovascular risk].
    Blacher J; Czernichow S; Horrellou MH; Conad J; David P; Chadefaux-Vekemans B; Ankria A; Galan P; Hercberg S; Ducimetière P
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):145-52. PubMed ID: 15787307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring the homocysteine level.
    Scott PM
    JAAPA; 2005 Sep; 18(9):57. PubMed ID: 16184873
    [No Abstract]   [Full Text] [Related]  

  • 18. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials.
    Pan Y; Guo LL; Cai LL; Zhu XJ; Shu JL; Liu XL; Jin HM
    Br J Nutr; 2012 Aug; 108(3):400-7. PubMed ID: 22244447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic determinants of plasma total homocysteine.
    Gellekink H; den Heijer M; Heil SG; Blom HJ
    Semin Vasc Med; 2005 May; 5(2):98-109. PubMed ID: 16047263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
    Righetti M; Serbelloni P; Milani S; Ferrario G
    Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.